Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Distribution, Metabolism, and Excretion of Gedatolisib in Healthy Male Volunteers After a Single Intravenous Infusion.

Houk BE, Alvey CW, Visswanathan R, Kirkovsky L, Matschke KT, Kimoto E, Ryder T, Obach RS, Durairaj C.

Clin Pharmacol Drug Dev. 2019 Jan;8(1):22-31. doi: 10.1002/cpdd.615. Epub 2018 Sep 26.

PMID:
30256541
2.

Nuclear rupture at sites of high curvature compromises retention of DNA repair factors.

Xia Y, Ivanovska IL, Zhu K, Smith L, Irianto J, Pfeifer CR, Alvey CM, Ji J, Liu D, Cho S, Bennett RR, Liu AJ, Greenberg RA, Discher DE.

J Cell Biol. 2018 Nov 5;217(11):3796-3808. doi: 10.1083/jcb.201711161. Epub 2018 Aug 31.

3.

Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects.

Dawra VK, Cutler DL, Zhou S, Krishna R, Shi H, Liang Y, Alvey C, Hickman A, Saur D, Terra SG, Sahasrabudhe V.

Clin Pharmacol Drug Dev. 2019 Apr;8(3):314-325. doi: 10.1002/cpdd.472. Epub 2018 May 22.

4.

Membrane fluctuations and acidosis regulate cooperative binding of 'marker of self' protein CD47 with the macrophage checkpoint receptor SIRPα.

Steinkühler J, Różycki B, Alvey C, Lipowsky R, Weikl TR, Dimova R, Discher DE.

J Cell Sci. 2018 Jul 16;132(4). pii: jcs216770. doi: 10.1242/jcs.216770.

5.

Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study.

Peeva E, Hodge MR, Kieras E, Vazquez ML, Goteti K, Tarabar SG, Alvey CW, Banfield C.

Br J Clin Pharmacol. 2018 Aug;84(8):1776-1788. doi: 10.1111/bcp.13612. Epub 2018 May 24.

6.

Clinical experience with moroctocog alfa (AF-CC) in younger paediatric patients with severe haemophilia A: Two open-label studies.

Rusen L, Kavakli K, Korth-Bradley J, Huard F, Rendo P, Fuiman J, Baumann JA, Smith L, Alvey C, Rupon J.

Haemophilia. 2018 Jul;24(4):604-610. doi: 10.1111/hae.13466. Epub 2018 Mar 26.

PMID:
29582525
7.

Novel Application of the Two-Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin.

Raje S, Callegari E, Sahasrabudhe V, Vaz A, Shi H, Fluhler E, Woolf EJ, Schildknegt K, Matschke K, Alvey C, Zhou S, Papadopoulos D, Fountaine R, Saur D, Terra SG, Stevens L, Gaunt D, Cutler DL.

Clin Transl Sci. 2018 Jul;11(4):405-411. doi: 10.1111/cts.12549. Epub 2018 Mar 25.

8.

Filomicelles Deliver a Chemo-Differentiation Combination of Paclitaxel and Retinoic Acid That Durably Represses Carcinomas in Liver to Prolong Survival.

Nair PR, Alvey C, Jin X, Irianto J, Ivanovska I, Discher DE.

Bioconjug Chem. 2018 Apr 18;29(4):914-927. doi: 10.1021/acs.bioconjchem.7b00816. Epub 2018 Mar 1.

9.

Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study.

Ruperto N, Brunner HI, Zuber Z, Tzaribachev N, Kingsbury DJ, Foeldvari I, Horneff G, Smolewska E, Vehe RK, Hazra A, Wang R, Mebus CA, Alvey C, Lamba M, Krishnaswami S, Stock TC, Wang M, Suehiro R, Martini A, Lovell DJ; Pediatric Rheumatology International Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG).

Pediatr Rheumatol Online J. 2017 Dec 28;15(1):86. doi: 10.1186/s12969-017-0212-y.

10.

Genome variation across cancers scales with tissue stiffness - an invasion-mutation mechanism and implications for immune cell infiltration.

Pfeifer CR, Alvey CM, Irianto J, Discher DE.

Curr Opin Syst Biol. 2017 Apr;2:103-114. doi: 10.1016/j.coisb.2017.04.005. Epub 2017 Apr 27.

11.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Domagrozumab (PF-06252616), an Antimyostatin Monoclonal Antibody, in Healthy Subjects.

Bhattacharya I, Pawlak S, Marraffino S, Christensen J, Sherlock SP, Alvey C, Morris C, Arkin S, Binks M.

Clin Pharmacol Drug Dev. 2018 Jun;7(5):484-497. doi: 10.1002/cpdd.386. Epub 2017 Sep 7.

PMID:
28881472
12.

SIRPA-Inhibited, Marrow-Derived Macrophages Engorge, Accumulate, and Differentiate in Antibody-Targeted Regression of Solid Tumors.

Alvey CM, Spinler KR, Irianto J, Pfeifer CR, Hayes B, Xia Y, Cho S, Dingal PCPD, Hsu J, Smith L, Tewari M, Discher DE.

Curr Biol. 2017 Jul 24;27(14):2065-2077.e6. doi: 10.1016/j.cub.2017.06.005. Epub 2017 Jun 29.

13.

Engineering macrophages to eat cancer: from "marker of self" CD47 and phagocytosis to differentiation.

Alvey C, Discher DE.

J Leukoc Biol. 2017 Jul;102(1):31-40. doi: 10.1189/jlb.4RI1216-516R. Epub 2017 May 18. Review.

14.

Confirmation of longer FIX activity half-life with prolonged sample collection after single doses of nonacog alfa in patients with haemophilia B.

Hua B, Wu R, Sun F, Luo B, Alvey C, Labadie R, Qu PR, Korth-Bradley JM, Rendo P.

Thromb Haemost. 2017 Jun 2;117(6):1052-1057. doi: 10.1160/TH16-10-0765. Epub 2017 Mar 23.

PMID:
28331929
15.

"Marker of Self" CD47 on lentiviral vectors decreases macrophage-mediated clearance and increases delivery to SIRPA-expressing lung carcinoma tumors.

Sosale NG, Ivanovska II, Tsai RK, Swift J, Hsu JW, Alvey CM, Zoltick PW, Discher DE.

Mol Ther Methods Clin Dev. 2016 Dec 7;3:16080. doi: 10.1038/mtm.2016.80. eCollection 2016.

16.

DNA Damage Follows Repair Factor Depletion and Portends Genome Variation in Cancer Cells after Pore Migration.

Irianto J, Xia Y, Pfeifer CR, Athirasala A, Ji J, Alvey C, Tewari M, Bennett RR, Harding SM, Liu AJ, Greenberg RA, Discher DE.

Curr Biol. 2017 Jan 23;27(2):210-223. doi: 10.1016/j.cub.2016.11.049. Epub 2016 Dec 15.

17.

Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers.

Menon S, Riese R, Wang R, Alvey CW, Shi H, Petit W, Krishnaswami S.

Clin Pharmacol Drug Dev. 2016 Sep;5(5):336-42. doi: 10.1002/cpdd.270. Epub 2016 Jun 26.

18.

Single- and multiple-dose pharmacokinetics of tofacitinib in healthy Chinese volunteers.

Krishnaswami S, Wang T, Yuan Y, Alvey CW, Checchio T, Peterson M, Shi H, Riese R.

Clin Pharmacol Drug Dev. 2015 Sep;4(5):395-9. doi: 10.1002/cpdd.202. Epub 2015 Jul 16.

PMID:
27137149
19.

Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food.

Lamba M, Wang R, Fletcher T, Alvey C, Kushner J 4th, Stock TC.

J Clin Pharmacol. 2016 Nov;56(11):1362-1371. doi: 10.1002/jcph.734.

20.

The Pharmacokinetics of Pregabalin in Breast Milk, Plasma, and Urine of Healthy Postpartum Women.

Lockwood PA, Pauer L, Scavone JM, Allard M, Mendes da Costa L, Alebic-Kolbah T, Plotka A, Alvey CW, Chew ML.

J Hum Lact. 2016 Aug 1;32(3):NP1-NP8. Epub 2016 Mar 9.

PMID:
26961752
21.

Macrophage engulfment of a cell or nanoparticle is regulated by unavoidable opsonization, a species-specific 'Marker of Self' CD47, and target physical properties.

Sosale NG, Spinler KR, Alvey C, Discher DE.

Curr Opin Immunol. 2015 Aug;35:107-12. doi: 10.1016/j.coi.2015.06.013. Epub 2015 Jul 13. Review.

22.

An age-structured model for the coupled dynamics of HIV and HSV-2.

Kapitanov G, Alvey C, Vogt-Geisse K, Feng Z.

Math Biosci Eng. 2015 Aug;12(4):803-40. doi: 10.3934/mbe.2015.12.803.

23.

A model for the coupled disease dynamics of HIV and HSV-2 with mixing among and between genders.

Alvey C, Feng Z, Glasser J.

Math Biosci. 2015 Jul;265:82-100. doi: 10.1016/j.mbs.2015.04.009. Epub 2015 May 4.

PMID:
25953482
24.

Effect of the gastrointestinal prokinetic agent erythromycin on the pharmacokinetics of pregabalin controlled-release in healthy individuals: a phase I, randomized crossover trial.

Chew ML, Plotka A, Alvey CW, Pitman VW, Alebic-Kolbah T, Scavone JM, Bockbrader HN.

Clin Drug Investig. 2015 May;35(5):299-305. doi: 10.1007/s40261-015-0281-y.

PMID:
25808394
25.

Safety, tolerability, and pharmacokinetics of pregabalin in children with refractory partial seizures: a phase 1, randomized controlled study.

Mann D, Liu J, Chew ML, Bockbrader H, Alvey CW, Zegarac E, Pellock J, Pitman VW.

Epilepsia. 2014 Dec;55(12):1934-43. doi: 10.1111/epi.12830. Epub 2014 Nov 6.

26.

Evaluation of the potential interaction between tofacitinib and drugs that undergo renal tubular secretion using metformin, an in vivo marker of renal organic cation transporter 2.

Klamerus KJ, Alvey C, Li L, Feng B, Wang R, Kaplan I, Shi H, Dowty ME, Krishnaswami S.

Clin Pharmacol Drug Dev. 2014 Nov;3(6):499-507. doi: 10.1002/cpdd.120. Epub 2014 May 23.

PMID:
27129125
27.

The effect of mild and moderate hepatic impairment on the pharmacokinetics of tofacitinib, an orally active Janus kinase inhibitor.

Lawendy N, Lamba M, Chan G, Wang R, Alvey CW, Krishnaswami S.

Clin Pharmacol Drug Dev. 2014 Nov;3(6):421-7. doi: 10.1002/cpdd.143. Epub 2014 Oct 1. Erratum in: Clin Pharmacol Drug Dev. 2018 Feb;7(2):222.

PMID:
27129117
28.

Pregabalin controlled-release pharmacokinetics in healthy volunteers: analysis of four multiple-dose randomized clinical pharmacology studies.

Chew ML, Alvey CW, Plotka A, Pitman VW, Alebic-Kolbah T, Scavone JM, Bockbrader HN.

Clin Drug Investig. 2014 Sep;34(9):627-37. doi: 10.1007/s40261-014-0221-2.

PMID:
25078977
29.

Pharmacokinetics of pregabalin controlled-release in healthy volunteers: effect of food in five single-dose, randomized, clinical pharmacology studies.

Chew ML, Plotka A, Alvey CW, Pitman VW, Alebic-Kolbah T, Scavone JM, Bockbrader HN.

Clin Drug Investig. 2014 Sep;34(9):617-26. doi: 10.1007/s40261-014-0211-4.

PMID:
25078976
30.

Evaluation of the effect of fluconazole and ketoconazole on the pharmacokinetics of tofacitinib in healthy adult subjects.

Gupta P, Chow V, Wang R, Kaplan I, Chan G, Alvey C, Ni G, Ndongo MN, LaBadie RR, Krishnaswami S.

Clin Pharmacol Drug Dev. 2014 Jan;3(1):72-7. doi: 10.1002/cpdd.71. Epub 2013 Oct 8.

PMID:
27128233
31.

A phase I, open-label, mass balance study of [(14)C] dacomitinib (PF-00299804) in healthy male volunteers.

Bello CL, Smith E, Ruiz-Garcia A, Ni G, Alvey C, Loi CM.

Cancer Chemother Pharmacol. 2013 Aug;72(2):379-85. doi: 10.1007/s00280-013-2207-9. Epub 2013 Jun 13.

PMID:
23760812
32.

Enhancing the state's BSN workforce with the right partner and the best technology.

Hern MJ, Johnson EG, Stogsdill V, Alvey C, Chlebowy D.

Ky Nurse. 2013 Apr-Jun;61(2):7-8. No abstract available.

PMID:
23617181
33.

Pharmacokinetics and pharmacodynamics of figitumumab, a monoclonal antibody targeting the insulin-like growth factor 1 receptor, in healthy participants.

Yin D, Sleight B, Alvey C, Hansson AG, Bello A.

J Clin Pharmacol. 2013 Jan;53(1):21-8. doi: 10.1177/0091270011432934. Epub 2013 Jan 24.

PMID:
23400740
34.

Bioequivalence assessment of a pregabalin capsule and oral solution in fasted healthy volunteers: a randomized, crossover study.

Bockbrader HN, Alvey CW, Corrigan BW, Radulovic LL.

Int J Clin Pharmacol Ther. 2013 Mar;51(3):244-8. doi: 10.5414/CP201765.

PMID:
23357837
35.

Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.

Landen JW, Zhao Q, Cohen S, Borrie M, Woodward M, Billing CB Jr, Bales K, Alvey C, McCush F, Yang J, Kupiec JW, Bednar MM.

Clin Neuropharmacol. 2013 Jan-Feb;36(1):14-23. doi: 10.1097/WNF.0b013e31827db49b.

PMID:
23334070
36.

Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease.

Burstein AH, Zhao Q, Ross J, Styren S, Landen JW, Ma WW, McCush F, Alvey C, Kupiec JW, Bednar MM.

Clin Neuropharmacol. 2013 Jan-Feb;36(1):8-13. doi: 10.1097/WNF.0b013e318279bcfa.

PMID:
23334069
37.

Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.

Gupta P, Alvey C, Wang R, Dowty ME, Fahmi OA, Walsky RL, Riese RJ, Krishnaswami S.

Br J Clin Pharmacol. 2012 Jul;74(1):109-15. doi: 10.1111/j.1365-2125.2012.04168.x.

38.

Lack of an effect of standard and supratherapeutic doses of linezolid on QTc interval prolongation.

Damle B, Labadie RR, Cuozzo C, Alvey C, Choo HW, Riley S, Kirby D.

Antimicrob Agents Chemother. 2011 Sep;55(9):4302-7. doi: 10.1128/AAC.01723-10. Epub 2011 Jun 27.

39.

Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects.

Malhotra B, Dickins M, Alvey C, Jumadilova Z, Li X, Duczynski G, Gandelman K.

Br J Clin Pharmacol. 2011 Aug;72(2):263-9. doi: 10.1111/j.1365-2125.2011.04007.x.

40.

Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.

Malhotra B, Alvey C, Gong J, Li X, Duczynski G, Gandelman K.

Br J Clin Pharmacol. 2011 Aug;72(2):257-62. doi: 10.1111/j.1365-2125.2011.03989.x.

41.

Evaluating lingual carcinoma for surgical management: what does volumetric measurement with MRI offer?

Boland PW, Watt-Smith SR, Pataridis K, Alvey C, Golding SJ.

Br J Radiol. 2010 Nov;83(995):927-33. doi: 10.1259/bjr/28782452.

42.

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics.

Tortorici MA, Toh M, Rahavendran SV, Labadie RR, Alvey CW, Marbury T, Fuentes E, Green M, Ni G, Hee B, Pithavala YK.

Invest New Drugs. 2011 Dec;29(6):1370-80. doi: 10.1007/s10637-010-9477-4. Epub 2010 Jul 2.

43.

The in vivo relationship between cross-sectional area and CT dose index in abdominal multidetector CT with automatic exposure control.

Meeson S, Alvey CM, Golding SJ.

J Radiol Prot. 2010 Jun;30(2):139-47. doi: 10.1088/0952-4746/30/2/003. Epub 2010 Jun 9.

PMID:
20530859
44.

MRI for definitive in utero diagnosis of cleft palate: a useful adjunct to antenatal care?

Descamps MJ, Golding SJ, Sibley J, McIntyre A, Alvey C, Goodacre T.

Cleft Palate Craniofac J. 2010 Nov;47(6):578-85. doi: 10.1597/09-070. Epub 2010 Feb 28.

PMID:
20509765
45.

Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin.

Whitfield LR, Porcari AR, Alvey C, Abel R, Bullen W, Hartman D.

J Clin Pharmacol. 2011 Mar;51(3):378-88. doi: 10.1177/0091270010366446. Epub 2010 Apr 22.

PMID:
20413454
46.

Clinical pharmacokinetics of pregabalin in healthy volunteers.

Bockbrader HN, Radulovic LL, Posvar EL, Strand JC, Alvey CW, Busch JA, Randinitis EJ, Corrigan BW, Haig GM, Boyd RA, Wesche DL.

J Clin Pharmacol. 2010 Aug;50(8):941-50. doi: 10.1177/0091270009352087. Epub 2010 Feb 10.

PMID:
20147618
47.

One-bead, one-compound peptide library sequencing via high-pressure ammonia cleavage coupled to nanomanipulation/nanoelectrospray ionization mass spectrometry.

Brown JM, Hoffmann WD, Alvey CM, Wood AR, Verbeck GF, Petros RA.

Anal Biochem. 2010 Mar 1;398(1):7-14. doi: 10.1016/j.ab.2009.10.044. Epub 2009 Nov 3.

PMID:
19891951
48.

Patterns of ovarian morphology in polycystic ovary syndrome: a study utilising magnetic resonance imaging.

Barber TM, Alvey C, Greenslade T, Gooding M, Barber D, Smith R, Marland A, Wass JA, Child T, McCarthy MI, Franks S, Golding SJ.

Eur Radiol. 2010 May;20(5):1207-13. doi: 10.1007/s00330-009-1643-8. Epub 2009 Nov 5.

PMID:
19890641
49.

Justifying multidetector CT in abdominal sepsis: time for review?

Meeson S, Alvey CM, Golding SJ.

Br J Radiol. 2009 Mar;82(975):190-7. doi: 10.1259/bjr/32680364. Epub 2008 Oct 27. Review.

PMID:
18955415
50.

A novel technique for vacuum assisted closure on injured tissue or in confined spaces.

Reed SF, Novosel TJ, Weireter LJ, Collins JN, Britt RC, Alvey C, Merkh K, Britt LD.

J Trauma. 2008 May;64(5):1406-7. doi: 10.1097/TA.0b013e318150733c. No abstract available.

PMID:
18469668

Supplemental Content

Support Center